Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis
Public ClinicalTrials.gov record NCT01087788. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Adult-Onset Active and Progressive Psoriatic Arthritis (PsA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in subjects with adult onset active and progressive Psoriatic Arthritis (PsA).
Study identification
- NCT ID
- NCT01087788
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 409 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2010 (Type not available)
- Primary completion
- Nov 2011 (Actual)
- Completion
- Aug 2015 (Actual)
- Last update posted
- Aug 1, 2018
2010 – 2015
United States locations
- U.S. sites
- 27
- U.S. states
- 17
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 961 | Birmingham | Alabama | — | — |
| 953 | Tuscaloosa | Alabama | — | — |
| 954 | Peoria | Arizona | — | — |
| 971 | Scottsdale | Arizona | — | — |
| 966 | Palm Desert | California | — | — |
| 952 | San Diego | California | — | — |
| 957 | Aventura | Florida | — | — |
| 962 | Fort Lauderdale | Florida | — | — |
| 959 | Orange Park | Florida | — | — |
| 958 | Vero Beach | Florida | — | — |
| 964 | Hagerstown | Maryland | — | — |
| 960 | Kalamazoo | Michigan | — | — |
| 969 | Eagan | Minnesota | — | — |
| 984 | Flowood | Mississippi | — | — |
| 965 | Florissant | Missouri | — | — |
| 950 | St Louis | Missouri | — | — |
| 985 | Brooklyn | New York | — | — |
| 963 | Asheville | North Carolina | — | — |
| 976 | Cleveland | Ohio | — | — |
| 951 | Middleburg Heights | Ohio | — | — |
| 970 | Oklahoma City | Oklahoma | — | — |
| 982 | Portland | Oregon | — | — |
| 972 | Duncansville | Pennsylvania | — | — |
| 975 | Dallas | Texas | — | — |
| 978 | Houston | Texas | — | — |
| 967 | San Antonio | Texas | — | — |
| 968 | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01087788, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 1, 2018 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01087788 live on ClinicalTrials.gov.